The "Trofile Assay" is a diagnostic laboratory blood test for patients who are HIV-positive. It is used to determine which co-receptor a person's HIV strain uses to enter their T-cells. This blood test is available for beneficiaries with diagnosed Acquired Immune Deficiency Syndrome (AIDS) who have evidence of viral replication and HIV-1 strain resistance to multiple anti-retroviral agents. The results of this test will assist in determining which anti-retroviral medication to provide for treatment.

Indications

DOM will provide reimbursement for the "Trofile Assay" for beneficiaries age 16 and over with the following restrictions/guidelines:

1. The assay is to be obtained only in anticipation of treatment of HIV/AIDS patients with CCR5 antagonist agents who:

    a. are "treatment experienced", in other words, have been previously treated with anti-retroviral regimen(s).

    b. have never received Maraviroc/Selzentry or other CCR5-antagonist agents.

    c. have been deemed to have "virologic failure", or failure to obtain sufficiently low HIV viral loads despite prior appropriate anti-retroviral therapy.

2. DOM authorizes coverage for one (1) assay per beneficiary, per lifetime. Repeated testing or testing in follow-up of therapy with CCR5 agents is not covered.

3. The treating physician has expertise in Infectious Diseases and/or treating HIV patients with anti-retroviral agents; **or** the treating physician has consulted with an Infectious Disease physician prior to requesting the assay.